Survey of the frequency of polypharmacy in multiple sclerosis patients: a study from the nationwide MS registry of Iran (NMSRI)-Guilan.

IF 2.8 Q3 CLINICAL NEUROLOGY
Neurodegenerative disease management Pub Date : 2026-10-01 Epub Date: 2026-08-17 DOI:10.1080/17582024.2026.2717246
Sahel Asgari, Alia Saberi, Hossein Daliri, Sepideh Atefrad, Mohaya Farzin
{"title":"Survey of the frequency of polypharmacy in multiple sclerosis patients: a study from the nationwide MS registry of Iran (NMSRI)-Guilan.","authors":"Sahel Asgari, Alia Saberi, Hossein Daliri, Sepideh Atefrad, Mohaya Farzin","doi":"10.1080/17582024.2026.2717246","DOIUrl":null,"url":null,"abstract":"<p><strong>Objuective: </strong>This study aimed to determine the prevalence of polypharmacy among patients with Multiple Sclerosis (MS) registered in the MS registry system of Gilan Province, Iran, and to analyze the relationships between polypharmacy and various demographic, clinical, and disease-related factors.</p><p><strong>Methods: </strong>This was a cross-sectional analytical study conducted on 1,282 MS patients registered in Gilan's MS registry system. Data were collected using a researcher-developed questionnaire that included questions on age, gender, marital status, education, occupation, smoking habits, comorbidities, family history of MS, and medication use.</p><p><strong>Results: </strong>The study found that 92.4% of patients used MS-related medications, and 65.5% used at least one non-MS medication. Polypharmacy was significantly associated with age, occupation, history of preexisting illnesses, comorbidities, number of coexisting diseases, and symptoms such as balance and urinary control disorders. Younger patients and those with multiple comorbidities were more likely to engage in polypharmacy.</p><p><strong>Conclusions: </strong>The results emphasize the high prevalence of polypharmacy in MS patients, underscoring the need for personalized treatment strategies. Educating patients about managing the risks of drug interactions and improving treatment adherence is crucial. The findings can inform healthcare policies to optimize the management of MS in similar regions.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"565-572"},"PeriodicalIF":2.8000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596921/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17582024.2026.2717246","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objuective: This study aimed to determine the prevalence of polypharmacy among patients with Multiple Sclerosis (MS) registered in the MS registry system of Gilan Province, Iran, and to analyze the relationships between polypharmacy and various demographic, clinical, and disease-related factors.

Methods: This was a cross-sectional analytical study conducted on 1,282 MS patients registered in Gilan's MS registry system. Data were collected using a researcher-developed questionnaire that included questions on age, gender, marital status, education, occupation, smoking habits, comorbidities, family history of MS, and medication use.

Results: The study found that 92.4% of patients used MS-related medications, and 65.5% used at least one non-MS medication. Polypharmacy was significantly associated with age, occupation, history of preexisting illnesses, comorbidities, number of coexisting diseases, and symptoms such as balance and urinary control disorders. Younger patients and those with multiple comorbidities were more likely to engage in polypharmacy.

Conclusions: The results emphasize the high prevalence of polypharmacy in MS patients, underscoring the need for personalized treatment strategies. Educating patients about managing the risks of drug interactions and improving treatment adherence is crucial. The findings can inform healthcare policies to optimize the management of MS in similar regions.

多发性硬化症患者使用多种药物的频率调查:来自伊朗全国多发性硬化症登记处(NMSRI)的研究-Guilan。
目的:本研究旨在了解伊朗吉兰省多发性硬化症(MS)登记系统中多发性硬化症(MS)患者的多重用药情况,并分析多重用药与各种人口统计学、临床和疾病相关因素的关系。方法:这是一项横断面分析研究,对在Gilan多发性硬化症登记系统中登记的1,282例多发性硬化症患者进行研究。数据收集使用研究人员开发的问卷,包括年龄、性别、婚姻状况、教育程度、职业、吸烟习惯、合并症、MS家族史和药物使用等问题。结果:研究发现92.4%的患者使用ms相关药物,65.5%的患者至少使用一种非ms药物。多种用药与年龄、职业、既往病史、合并症、并存疾病数量以及平衡和泌尿控制障碍等症状显著相关。年轻患者和有多种合并症的患者更有可能参与多种药物治疗。结论:结果强调多发性硬化症患者中多种药物的高患病率,强调个性化治疗策略的必要性。教育患者如何管理药物相互作用的风险和提高治疗依从性至关重要。研究结果可以为医疗保健政策提供信息,以优化类似地区的MS管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
35
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书